Literature DB >> 10595830

Structure-function correlations of growth hormone or/and prolactin-producing pituitary adenomas: an in vitro study with the reverse hemolytic plaque assay.

E Thodou1, G Kontogeorgos, E Kyrodimou, H Salla, L Ramyar, E Vamvassakis, G Piaditis, N Anagnostopoulos, S Tzanis, A Levedis, D Rologis, S L Asa.   

Abstract

The purpose of this study was to detect in vitro growth hormone (GH) and prolactin (PRL) secretion from adenomas clinically associated with GH or PRL hypersecretion. The reverse hemolytic plaque assay (RHPA) was applied in order to reveal possible differences among various morphologic adenoma types, and to examine the inhibitory effects of octreotide on GH release as well. The 20 surgically resected pituitary adenomas studied included 15 from acromegalic patients and 5 from patients with hyperprolactinemia. All adenomas were diagnosed by histology, immunocytochemistry and electron microscopy. Among tumors associated with acromegaly, 5 were densely granulated (DG), 5 were sparsely granulated (SG) somatotroph (SM) adenomas, 2 were mammosomatotroph (MSM) and 3 mixed somatotroph-lactotroph cell (mixed SM-LT) adenomas; tumors causing hyperprolactinemia included 4 lactotroph (LT) adenomas and 1 mixed SM-LT adenoma. GH release assessed by the RHPA corresponded to in vivo hormone secretion and to tissue immunoreactivity. Statistical analysis showed significant differences among all morphologic types of SM adenomas, exclusive of SG-SM adenomas compared to mixed SM-LT adenomas. The mean plaque size in DG-SM and MSM adenomas was significantly greater than that of SG-SM and mixed SM-LT adenomas, indicating higher GH secretion by the former two types during the same incubation time. PRL secretion was documented in 2 mixed SM-LT adenomas. Plaques for PRL, but not for GH were formed in all LT adenomas. In all SM and LT adenomas, cells producing large plaques represented a minority of the plaque-forming cell population, however, they accounted for the largest part of the total plaque area, thus the largest part of hormone secretion. Octreotide effects on GH release were studied in 6 adenomas by the RHPA. Octreotide treatment induced a rapid and significant reduction in GH secretion by SM cells in vitro, with a selective effect on high-secreting cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10595830     DOI: 10.1007/BF03343628

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

Review 1.  Heterogeneity of growth hormone production in human pituitary tumour cells.

Authors:  J R Davis
Journal:  Clin Endocrinol (Oxf)       Date:  1991-01       Impact factor: 3.478

2.  Human prolactin-producing adenomas and bromocriptine: a histological, immunocytochemical, ultrastructural, and morphometric study.

Authors:  G T Tindall; K Kovacs; E Horvath; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1982-12       Impact factor: 5.958

3.  The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status.

Authors:  J C Reubi; A M Landolt
Journal:  J Clin Endocrinol Metab       Date:  1989-04       Impact factor: 5.958

4.  Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.

Authors:  J Li; L Stefaneanu; K Kovacs; E Horvath; H S Smyth
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

5.  Analysis of mammosomatotropic cells in normal and neoplastic human pituitary tissues by the reverse hemolytic plaque assay and immunocytochemistry.

Authors:  R V Lloyd; D Anagnostou; M Cano; A L Barkan; W F Chandler
Journal:  J Clin Endocrinol Metab       Date:  1988-06       Impact factor: 5.958

6.  Regulation of growth hormone secretion and messenger ribonucleic acid accumulation in human somatotropinoma cells in vitro.

Authors:  J R Davis; E M Wilson; M E Vidal; A P Johnson; S S Lynch; M C Sheppard
Journal:  J Clin Endocrinol Metab       Date:  1989-10       Impact factor: 5.958

7.  A Serum-Free System for Primary Cultures of Human Pituitary Adenomas.

Authors:  Eleni Thodou; Lily Ramyar; Arthur I. Cohen; William Singer; Sylvia L. Asa
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

8.  Heterogeneity of growth hormone (GH) release by individual pituitary adenoma cells from acromegalic patients, as determined by the reverse hemolytic plaque assay: effects of SMS 201-995, GH-releasing hormone and thyrotropin-releasing hormone.

Authors:  L J Hofland; P M van Koetsveld; C C van Vroonhoven; S Z Stefanko; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  1989-03       Impact factor: 5.958

9.  Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas.

Authors:  S Ezzat; H S Smyth; L Ramyar; S L Asa
Journal:  J Clin Endocrinol Metab       Date:  1995-03       Impact factor: 5.958

10.  Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.

Authors:  Y Greenman; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.